June 28, 2010
Advaxis Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial
Advaxis Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial
NORTH BRUNSWICK, N.J.—-Advaxis, Inc., , the live, attenuated Listeria monocytogenes biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia , commonly known as cervical dysplasia.
Read more on Business Wire via Yahoo! Finance
Avino Silver and Gold Mines Ltd.: San Gonzalo Bulk Sampling Program Update
VANCOUVER, BRITISH COLUMBIA– – Avino Silver and Gold Mines Ltd. is pleased to report that milling operations commenced on May 22, 2010, with the treatment of stockpiled ET copper ore from the main Avino vein from past mining.
Read more on CCNMatthews via Yahoo! Finance
Written by: admin
Filed Under: Breaking News
Tags: Advaxis, Cervical, Clinical, Completes, Dosing, Dysplasia, Group, Patient, Phase, Trial, Vanguard
Trackback URL: http://thepennystockstowatch.com/2010/06/advaxis-completes-dosing-of-vanguard-patient-group-in-phase-ii-cervical-dysplasia-clinical-trial/trackback/
